Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research

Inflammation found to underlie cardiology, oncology, and other key fields as BioAge Labs, Inc. advances research
Inflammation links major diseases

BioAge Labs, Inc. draws attention to inflammation as a common element driving diseases across diverse medical fields. The statement echoes insight from Harvard cardiologist Peter Libby, featured in a recent New York Times article, who argues that disciplines such as cardiology, oncology, neurology, and rheumatology are now converging around inflammation’s central role.

This shift is reframing approaches to research and treatment, suggesting that targeting inflammatory processes may hold promise for breakthrough therapies in multiple major diseases. The recognition of this shared underlying process is prompting interdisciplinary collaboration and could accelerate medical innovation.

BioAge Labs, Inc. recently began a Phase 2 clinical trial for a drug targeting obesity and cardiovascular risk. The company is also planning a proof-of-concept eye study. These initiatives highlight BioAge's ongoing efforts in treatments that intersect with inflammation’s role in disease.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.